




TSE JASDAQ 4978


ReproCELL Inc.

**Advancing Towards
Regenerative Medicine**

August 13th, 2015




Using the global infrastructure that has been built today, we are advancing the foundation for a Regenerative Medicine R&D and Sales Platform.



Regenerative Medicine Market is expected to reach JPY 53 Trillion by 2050.

■ Growth of the Global Regenerative Medicine Market ¹



Source (Japanese):

1. 経産省「再生医療の実用化・産業化に関する研究会の最終報告」
2. 平成 24 年度 中小企業支援調査（再生医療の実用化・産業化に係る調査事務等）報告書


■ Reprocell Group Long Term Vision



We are proactively moving forward in the regenerative medicine field from a position of high feasibility by also looking to collaborate with somatic stem cell technologies.

Regenerative Medicine Roadmap

Business Scale



Development of cell based Medicines using the iPS Stem Cells

Application of our group's cutting edge culture technology.

Development of cell based medicines using Somatic Stem Cells

Tech Collaboration with Portfolio Companies of Joint Venture Fund (Cell Innovation Partners, L.P.)

Development of Culture Medium and Reagents for Regenerative Medicine

Application of our group's cutting edge culture technology

Course of Expansion

Global Market Size (Est.)

2020

2050

JPY 1.1 Trillion

JPY 38.4 Trillion

JPY 90.1 Billion

JPY 3.4 Trillion

出所：平成 24 年度 中小企業支援調査
(再生医療の実用化・産業化に係る調査事務等) 報告書

REPROCELL GROUP COMPANIES



bioserve

stemgent

reinnervate

Taking full advantage of our superior platform to become the leading company in regenerative medicine by maximizing our superior group infrastructure.

Cutting edge iPS Stem Cell Culture Technology

Global R&D Network

Strong Technical Platform for iPS Stem Cell

University of Tokyo

Harvard University

ReproCELL Group

reinnervate

REPROCELL
stemgent

bioserve

Massachusetts Institute of Technology

Durham University

Kyoto University

Keio University

